Although anti-HER2 targeted therapies such as trastuzumab and pertuzumab have demonstrated high efficacy in combination for HER2-positive breast cancer, no effect has been observed for negative cases [1, 2]. The gene discussed is ERBB2; the disease is breast carcinoma.